Results 61 to 70 of about 8,552 (153)
Experimental Physiology, EarlyView.Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu +4 more
wiley +1 more source
Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease
Bone Research, 2021 Bone-produced fibroblast growth factor 23 (FGF23) increases in response to inflammation and iron deficiency and contributes to cardiovascular mortality in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL or lipocalin 2; LCN2
Guillaume Courbon +10 more
doaj +1 more source
Proteomic signatures of equine dental tooth tissues in ageing and disease
Equine Veterinary Journal, Volume 58, Issue 6, Page 1552-1569, November 2026.Abstract Background Ageing and dental disease in horses lead to structural and functional deterioration of dental tissues, yet their molecular signatures remain poorly characterised. Understanding how these processes alter the protein composition of enamel, dentin, cementum and pulp is essential for improving equine oral health and identifying ...
Anders Jensen +8 more
wiley +1 more source
FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults [PDF]
Hypertension, 2018 Blacks have the highest prevalence of hypertension in the United States. Higher levels of FGF23 (fibroblast growth factor-23) have been associated with worse cardiovascular outcomes. Whether FGF23 is associated with rising blood pressure (BP) and racial differences in incident hypertension is unclear. We studied 1758 adults (45.0±3.7 years;
Akhabue E. +10 more
openaire +3 more sources
Short‐term fasting of mice elevates circulating fibroblast growth factor 23 (
Acta Physiologica, 2023 AbstractAimsPhosphate and vitamin D homeostasis are controlled by fibroblast growth factor 23 (FGF23) from bone suppressing renal phosphate transport and enhancing 24‐hydroxylase (Cyp24a1), thereby inactivating 1,25(OH)2D3. Serum FGF23 is correlated with outcomes in several diseases. Fasting stimulates the production of ketone bodies.
Martina Feger +6 more
openaire +2 more sources
Chinese Journal of Physiology, 2023 Acute cardiomyopathy is a significant global health concern and one of the leading causes of death in developed countries. Prior studies have shown an association between acute cardiomyopathy and low vitamin D levels.
Chieh-Jen Wu, Yu-He Li, Hsin-Hung Chen
doaj +1 more source
Vitamin D: Physiology, Pharmacology and Clinical Evidence for Supplementation—A Narrative Review
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.ABSTRACT Vitamin D is a nutrient and prohormone obtained from diet and supplements and synthesized in the skin. It is essential for calcium and phosphate homeostasis and skeletal health and influences multiple extra‐skeletal processes, yet deficiency remains common worldwide.
Jyrki K. Virtanen
wiley +1 more source
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism [PDF]
Pediatric Nephrology, 2009 There are a number of hypophosphatemic disorders due to renal phosphate wasting that cannot be explained by elevated levels of parathyroid hormone. The circulating factors responsible for the phosphaturia have been designated as phosphatonins. Studies of patients with tumor-induced osteomalacia and other genetic diseases of phosphate metabolism have ...
Jyothsna, Gattineni, Michel, Baum
openaire +2 more sources
Cell Proliferation, Volume 59, Issue 10, October 2026.During development, the oxygen‐sensitive transcription factor Zeb2 restrains astrocyte proliferation and maturation to ensure balanced retinal angiogenesis. In disease, it promotes the neurotoxic A1 astrocyte phenotype and inflammation, thereby promoting reparative revascularization over pathological neovascularization.
Jing Liu +5 more
wiley +1 more source
Hemodialysis International, Volume 30, Issue 4, Page 689-697, October 2026.ABSTRACT Introduction Tenapanor, a minimally absorbed intestinal NHE3 inhibitor approved for hyperphosphatemia in dialysis, lowers phosphate and reduces intestinal sodium absorption. Its sodium–water signal may have implications beyond phosphate but remains poorly separated from diarrhea‐mediated losses and dialysis prescription artifacts. Methods This
Lucas Maciel de Almeida Corrêa +8 more
wiley +1 more source